Novartis

R&D

Novartis’ Kesimpta, ECTRIMS 2022, and relapsing multiple scl...

Having presented new data at last year’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting – where the safety and efficacy of Novartis’ Kesimpta (

News

Novartis licenses cocaine use disorder therapy to Stalicla

Swiss biotech Stalicla has continued to diversify its pipeline from a focus on autism therapies with a deal to license Novartis' mavoglurant, in clinical trials for cocaine use disorder (CU

News

Free access to Zolgensma curbed, says Novartis

Novartis' programme providing free access to its spinal muscular atrophy (SMA) gene therapy Zolgensma is being scaled back to a dozen countries worldwide, according to the company.

News

Novartis agrees $245m settlement over Exforge generics delay

Novartis has said it will pay $245 million to resolve civil litigation in the US, which accuses it of a 'pay for delay' scheme involving generics of its high blood pressure therapy Exforge.

News

ASH roundup: late breakers take the stage

The final day of the ASH congress always includes a session on late-breaking studies, and this year was no exception, with presentations on Novartis' iptacopan in paroxysmal nocturnal haemo

News

Novartis builds case for iptacopan as oral rival to PNH inje...

Novartis has a second positive phase 3 trial in the bag for its targeted factor B inhibitor iptacopan, vying to become an oral alternative to injectable therapies for ultra-rare blood disor

Novartis’ Kesimpta, ECTRIMS 2022, and relapsing multiple scl...

Novartis licenses cocaine use disorder therapy to Stalicla

Free access to Zolgensma curbed, says Novartis

Novartis agrees $245m settlement over Exforge generics delay

ASH roundup: late breakers take the stage

Novartis builds case for iptacopan as oral rival to PNH inje...

AZ claims another win for Imfinzi in frontline liver cancer

Using AI-driven synthetic personas to take your insights fur...

Novartis

Editor's Picks